Synchron Launches Stentrode Home System, Enabling Fully Wireless BCI Use Outside Clinical Settings

Synchron has received FDA 510(k) clearance for its Stentrode Home System, marking a significant commercial milestone for the endovascular brain-computer interface company and representing one of the first times a fully implanted BCI has been authorized for unsupervised use outside a hospital or clinical environment. The announcement, made at the company's New York headquarters on Monday, positions Synchron as the first BCI manufacturer to bridge the gap between clinical trials and real-world, independent patient use.

The Stentrode device is implanted via a minimally invasive endovascular procedure — threading a stent-electrode array through the jugular vein and into a blood vessel adjacent to the motor cortex — avoiding the need for open-brain surgery. The newly cleared Home System pairs the implant with a redesigned external transmitter worn on a lightweight vest, a companion tablet interface, and an over-the-air software update pipeline that allows Synchron's clinical team to tune device parameters remotely. The company says the full setup takes a patient under ten minutes to don each morning.

Early commercial availability will be limited to patients with ALS and other upper-limb paralysis conditions, with a controlled rollout through select neurology centers in the United States and Australia. Synchron has confirmed partnerships with Mount Sinai Health System and Royal Melbourne Hospital as initial certified implant sites. Pricing has not been disclosed, though the company confirmed it is actively engaged in coverage discussions with major U.S. payers and the Centers for Medicare and Medicaid Services.

The clearance follows data from Synchron's COMMAND pivotal trial, which enrolled 22 participants across four sites and demonstrated that users could reliably control computers, smartphones, and smart-home devices using neural signals with a median accuracy above 90 percent after six months of use. The trial also recorded no serious device-related adverse events over a combined follow-up period exceeding 800 patient-months, a safety profile the FDA cited in its clearance decision.

Industry analysts have noted the timing is significant. With Neuralink still operating under its PRIME study's investigational device exemption and Blackrock Neurotech focused on research-grade systems, Synchron's clearance gives it a meaningful first-mover advantage in the emerging consumer-adjacent BCI market.

Synchron CEO Tom Oxley called the clearance "the day neurotech becomes a real medical product category," adding that the company plans to expand indications to stroke and spinal cord injury within the next 18 months pending additional regulatory submissions.